Introduction {#Sec1}
============

Epithelial Ovarian Cancer (EOC) is a heterogeneous disease with five major histologic types^[@CR1],\ [@CR2]^: high-grade serous carcinoma, which accounts for the approximately 70% of all EOC cases, and clear cell (10%), endometrioid (10%), mucinous (3%), and low-grade serous carcinomas (\<5%). These subtypes differ in terms of histopathology, morphology, and genomic alterations and are considered distinct diseases, which require careful diagnosis and specific therapies that are critical for successful treatment^[@CR3]^. Ovarian granulosa cell tumors do not have epithelial origin but are the most common sex cord-stromal tumor and represent 5% of all ovarian malignancies^[@CR4]^.

Based on molecular profiles, disease development and prognosis, the different histological subtypes can be hierarchically grouped into type I and type II^[@CR5]^. Type I tumors are slow growing and encompass low-grade serous, low-grade endometrioid, mucinous and clear cell carcinomas characterized by mutations in *KRAS*, *BRAF*, and *PIK3CA* and by the absence of *TP53* mutations^[@CR6]^. Type II tumors are highly aggressive and encompass high-grade serous tumors as a typical representative, as well as high-grade endometrioid and undifferentiated carcinomas with disruption of *TP53* ^[@CR7]^. Type II tumors have expression profiles that cluster separately from type I tumors and are characterized by genomic instability, extremely aggressive clinical progression and poor prognosis^[@CR8]--[@CR11]^.

A comprehensive view of the germline variation associated with cancer risk^[@CR12]--[@CR22]^ and somatic alterations in high-grade serous ovarian carcinoma has recently emerged (Supplementary Table [1](#MOESM2){ref-type="media"})^[@CR8],\ [@CR23]--[@CR25]^. These tumors were characterized by somatic *TP53* mutations in 96% of all samples and low prevalence mutations in nine additional genes such as *NF1*, *BRCA1*, *BRCA2*, *RB1* and *CDK12*. Recurrent large copy number alterations were observed (8 gains and 22 losses) and included genes such as *MYC* and *KRAS* (gain) and *PTEN*, *RB1*, and *NF1* (loss). Many of these larger gains and losses were observed in the majority of tumors, highlighting the genomic instability of high-grade serous ovarian carcinoma. In addition, analyses of complete genomes for sixteen low stage high grade serous EOC revealed frequent *TP53* mutations, tetraploidy and homologous recombination repair defects^[@CR26]^.

However, other non-serous forms of ovarian cancer contribute to significant morbidity and mortality yet few systematic studies have been conducted to characterize their germline and somatic mutational profile. Recently, genome-wide association studies identified three susceptibility loci and analysis of somatic alterations revealed a more detailed view of mucinous ovarian cancer^[@CR27],\ [@CR28]^. Most published studies, however, report germline or somatic targeted sequencing of a limited number of genes^[@CR9],\ [@CR29]--[@CR31]^, or exome studies with a limited number of samples^[@CR32]^ (Supplementary Table [1](#MOESM2){ref-type="media"}). A comparison between endometrioid uterine and endometrioid ovarian carcinomas using select exon capture of mutation profiles revealed that despite a possible common origin in endometriosis these tumors display differences in their mutation profile^[@CR33]^.

In order to further explore the genomic landscape of non-serous ovarian cancer, we conducted exome sequencing of ten non-serous (endometrioid, mucinous, and granulosa) tumors and performed targeted gene sequencing of exons in 1,321 genes for 28 additional tumor samples including the clear-cell subtype. We report mutational and copy number profiles indicating that non-serous ovarian cancer is genomically distinct from serous EOC and displays similarities to non-serous endometrial uterine cancer.

Results {#Sec2}
=======

Tumors were chosen by interrogating Moffitt tissue bank for cases that fulfilled the following criteria: a) non-serous histology; b) Stage I; and c) available fresh-frozen tissue; d) available matched normal blood or tissue. Whole exome sequencing was performed on 9 tumor/normal matched pairs, and one tumor only referred to as the ES (exome sequencing) cohort (Table [1](#Tab1){ref-type="table"}). No case with clear cell tumor fulfilled the selection criteria. A median of 184 million reads and 17.5GB of exome sequencing data per sample was obtained. We annotated 32,965 somatic mutations within 100 bases of the exome target region (median = 1,299; range 829--15,767 per tumor, Supplementary Table [3](#MOESM2){ref-type="media"}) for an overall rate of mutations of 12.1 per Mb. The overview of the study is depicted in a REMARK (Reporting recommendations for tumor marker prognostic studies)-style diagram (Supplementary Figure [1](#MOESM1){ref-type="media"}).Table 1Samples used in exome sequencing.CaseHistologyGradeStageAge at diagnosisTissue of normal DNAMain findingsOV1Endometrioid AdenocarcinomaFIGO 21C48UterusGlandular and sparse solid patterns. Focal squamous differentiation.OV2Endometrioid AdenocarcinomaFIGO 21C63BloodGlandular pattern.OV3Endometrioid AdenocarcinomaFIGO 11A28BloodGlandular and villoglandular patterns. Adenofibroma component.OV4Endometrioid AdenocarcinomaFIGO 21C49BloodGlandular and sparse solid patterns.OV5Endometrioid AdenocarcinomaFIGO 11C53BloodGlandular pattern. Focal squamous differentiation.OV6Endometrioid AdenocarcinomaFIGO 11A54BloodGlandular pattern.OV7Granulosa Cell tumorUngraded1A57N/AAdult type, trabecular pattern.OV8Mucinous AdenocarcinomaNS1A54BloodEndocervical type. *BRCA2* germline pathogenic variant.OV9Mucinous AdenocarcinomaNS1A41BloodEndocervical type.OV10Mucinous AdenocarcinomaNS1C44BloodEndocervical type. LMP neoplasm component.N/A, not available; NS, grading not standardized; LMP, low malignant potential.

Common cancer exome alterations {#Sec3}
-------------------------------

MutSigCV_1.4 was used to identify significantly mutated genes, but no genes were observed with significant q-value. Only three genes were observed with q-value \<1: *GOLGA6L1* (q = 0.62), *PTEN* (q = 0.73), and *OR2T33* (q = 0.76). No single confident mutated position (\<1% in 1000 Genomes and 238 TCC normal samples, passing manual review) was observed in more than three samples, and only *PTEN* stood out as a gene containing truncating mutations in three samples (Fig. [1A](#Fig1){ref-type="fig"}). Mutations were mapped and compared to the COSMIC database (<http://cancer.sanger.ac.uk/cosmic>). Several COSMIC cancer genes were found to have various mutations in multiple samples, including *PTEN*, *PIK3CA*, *BRCA2*, and *ATM* (Fig. [1A](#Fig1){ref-type="fig"}, Supplementary Table [4](#MOESM2){ref-type="media"}). Several known cancer mutations were seen in unique samples (*KRAS* p.G12D, *BRAF* p.D594G, *NF1* p.R1362\*, and *ZFAND1* p.R130\*). Only one sample (OV8) had a *TP53* mutation (p.G245D, seen 22x in TCGA breast, ovarian, and colorectal cancers).Figure 1Mutation profile in non-serous ovarian cancer. (**A**) Mutation profiles showing mutations identified using tumor-normal pair analysis. Each column corresponds to exome sequencing data for one ovarian tumor. Rows correspond to presence or absence of mutation in the sample. (**B**) Mutation profiles showing mutations identified using tumor-only analysis. Each column corresponds to exome sequencing of one ovarian tumor. Rows correspond to presence or absence of mutation in the sample. (**C**) Mutation profiles showing mutations identified in target gene sequencing. Each column corresponds to one ovarian tumor. Rows correspond to presence or absence of mutation in the sample. Blue boxes highlight the high prevalence of specific mutations in certain histological subtypes. Sample histologies are shown in different colors representing endometrioid (blue), mucinous (yellow), clear cell (white), and granulosa cell (grey) histologies. Missense mutations and truncations are shown as red and black boxes, respectively. Star indicates samples with identified *POLE* proofreading domain mutations. (**D**) Frequency of the most common mutations in different tumor types and histologies. The radar graph display the frequency of various mutations across datasets, clockwise from top: ovarian serous cystadenocarcima (TCGA), serous endometrial uterine cancer (TCGA), non-serous ovarian tumors (exome sequencing, this study), non-serous ovarian tumors (target gene sequencing, this study), and non-hypermutable endometrial uterine cancers (TCGA). Height of the peak from the middle of the radar indicates the frequency of individuals with a mutation in the given gene.

To ensure no mutations were missed due to local low coverage in the normal sample, we also identified genotypes using GATK on tumor samples alone. Mutations previously observed in COSMIC were retained. No further *TP53* mutation was observed. Additional cancer mutations were detected in OV7 (*FOXL2* p.C134W) and OV9 (*KRAS* p.G12V) (Fig. [1B](#Fig1){ref-type="fig"}). We observed a somatic p.Q257H variant in *BRAF* but the functional consequence of this alteration is unclear. Although *NRAS* was well covered (97.4% bases covered ≥10× on average) in our dataset, no mutations were observed, suggesting it may not be a common driver of mucinous tumors. Interestingly, for sample OV10, the *KRAS* variant was only called in the tumor/normal analysis (Fig. [1A](#Fig1){ref-type="fig"}) but not in tumor only analysis (Fig. [1B](#Fig1){ref-type="fig"}). The variant base was present in 4/23 reads in the tumor and 0/11 reads in the normal. We confirmed this variant is present in heterozygosis by Sanger sequencing in OV10.

GATK-based analysis of OV10 also detected a large insertion in *PIK3CA*, a missense variant in *ARID1A* (p.Ala532Thr) observed in only 2/25 tumor and 0/100 normal reads, and an *NF1* large insertion that introduces a stopgain. Sanger sequencing did not confirm those changes suggesting that they may have been incorrectly called or that only a small percentage of cells in the tumor carry that variant.

We also assessed germline variants in the exome sequencing data from the normal samples available from 9 cases (Supplementary Tables [9](#MOESM2){ref-type="media"} and [10](#MOESM2){ref-type="media"}; except OV7) focusing on a set of genes implicated in ovarian cancer^[@CR34]^. Only one clearly pathogenic variant, *BRCA2*:c.6944_6947delTAAA (p.Ile2315Lysfs) (OV8) variant and few variants of uncertain clinical significance were identified (Supplementary Table [10](#MOESM2){ref-type="media"}). We confirmed the *BRCA2* mutation using Sanger sequencing. A list of all non-synonymous variants called using a combination of Mutec and Strelka, including variants within the SeqCap EZ Exome v3 regions + 100 bp flanking sequence, is shown in Supplementary Table [11](#MOESM2){ref-type="media"}. We excluded variants observed in 1000 Genomes Project (Phase 3) or in an internal dataset of 238 adjacent normal samples at ≥5% frequency.

Target sequencing {#Sec4}
-----------------

We expanded our investigation to include an additional 23 non-serous EOC tumors and five granulosa cell tumors with sequencing data covering 1,321 genes selected based on their suspected involvement in cancer, independently of the data obtained during exome sequencing. They were selected through a review of the literature, mutation databases and key pathways in tumorigenesis such as growth factor signaling, DNA damage response, p53 signaling, cell cycle control and apoptosis^[@CR35]^ (Table [2](#Tab2){ref-type="table"}, Supplementary Table [2](#MOESM2){ref-type="media"}). Approximately 1.4 GB of targeted gene sequencing data per sample was obtained by sequencing 1,321 genes covering 3.8 Mb (Supplementary Table [5](#MOESM2){ref-type="media"}). Mutations were cross referenced with COSMIC to identify driver mutations (Fig. [1C](#Fig1){ref-type="fig"}, Supplementary Table [6](#MOESM2){ref-type="media"}).Table 2.Samples used in target gene sequencing.CaseHistologyAge at diagnosisTG1Endometrioid carcinoma, squamous differentiationNATG2Endometrioid adenocarcinoma51TG3Endometrioid adenocarcinoma54TG4Endometrioid adenocarcinoma71TG5Endometrioid adenocarcinoma60TG6Endometrioid adenocarcinoma56TG7Endometrioid adenocarcinoma61TG8Endometrioid adenocarcinoma58TG9Endometrioid adenocarcinoma54TG10Endometrioid adenocarcinoma50TG11Endometrioid adenocarcinoma61TG12Endometrioid adenocarcinoma52TG13Endometrioid adenocarcinoma51TG14Endometrioid adenocarcinoma79TG15Granulosa CellNATG16Granulosa CellNATG17Granulosa Cell61TG18Granulosa Cell73TG19Granulosa Cell66TG20Mucinous cystadenocarcinoma78TG21Mucinous cystadenocarcinoma30TG22Mucinous, carcinoma55TG23Mucinous, carcinoma51TG24Clear cell, carcinoma62TG25Clear cell, carcinoma64TG26Clear cell, carcinoma53TG27Clear cell adenocarcinoma63TG28Clear cell, carcinoma63

We found 11 unique *TP53* mutations, seen in 10/28 (36%) tumors. *TP53* mutations were prevalent in endometrioid (6/14) and mucinous (3/4) subtypes but less frequent in clear cell (1/5) and absent in granulosa cell (0/5). We also observed the presence of *FOXL2* p.C134W mutation in 4/5 (80%) of the additional granulosa cell samples. Although other *FOXL2* mutations were observed in different samples, the p.C134W driver mutation was only observed in the granulosa cell subtype. *KRAS* mutations were observed in 3/4 (75%) of additional mucinous samples and 3/14 (21%) of additional endometrioid samples. *ARID1A* and *CTNNB1* were mutated more frequently in endometrioid tumors (6/14, 43% and 7/14, 50% respectively), further suggesting these are important contributors to that tumor type^[@CR31]^. *ARID1A* truncating mutations were also recurrently observed in 2/5 (40%) clear cell tumors.

Comparison to TCGA serous ovarian and serous/non-serous endometrial cancers {#Sec5}
---------------------------------------------------------------------------

We compared mutation patterns observed in our set of 9 whole exome ovarian tumors and our set of 23 targeted gene ovarian tumors to TCGA studies on serous ovarian^[@CR8]^ and endometrial cancers^[@CR36]^ at genes known to be mutated in these diseases (Fig. [1D](#Fig1){ref-type="fig"}). Serous ovarian cancer is marked by very high mutation rate of *TP53* (96%) and of few other cancer genes. Serous endometrial also has a high *TP53* mutation rate of 74%, as well as *PIK3CA* (36%), *FBXW7* (26%), and *PPP2R1A* (23%). *TP53* mutation rates were much lower in our non-serous OC samples: 10% in ES, and 36% in our TGS cohort. *PIK3CA* mutation rates were, on average, higher in our non-serous OC samples compared to serous cancers. We observed higher mutation rates in each of the following genes in non-serous ovarian samples compared to serous ovarian and serous endometrial: *PTEN*, *PIK3R1*, *CTNNB1*, *ARID1A*, and *KRAS*. Many of these genes are frequently mutated in non-ultramutated endometrioid uterine cancer (Fig. [2](#Fig2){ref-type="fig"}), particularly *PTEN*, *PIK3CA*, *PIK3R1*, *CTNNB1*, *ARID1A*, and *KRAS* ^[@CR36]^.Figure 2Mutation signatures of non-serous ovarian tumors. (**A**) Incidence of most probable mutation signatures in each sample by raw mutation count (left) or mutation fraction (right). The inferred mutation signature is listed below sample names. Parentheses indicate lower confidence in the assigned signature due to lower mutation counts. (**B**) Mutation distribution similar to Signature 10 (*POLE* proofreading domain dysfunction) from^[@CR38]^. (**C**) Mutation distribution similar to Signature 18 from^[@CR38]^.

POLE mutations {#Sec6}
--------------

One endometrioid sample (OV4) was observed to have very high mutation count (Fig. [1](#Fig1){ref-type="fig"}) (Supplementary Table [3](#MOESM2){ref-type="media"}). Further investigation revealed that this sample contained a *POLE* p.V411L mutation in the proofreading domain that has been previously observed in endometrioid uterine carcinoma^[@CR36]^ and colorectal cancer^[@CR37]^. Two additional *POLE* mutations were observed in endometrioid ovarian samples in our expanded TGS cohort: p.P286R (TG3) and another p.V411L (TG10).

Mutation signatures {#Sec7}
-------------------

Examining the pattern of nucleotide changes, *i.e*. the mutational signatures, in a tumor can suggest mechanisms that may have contributed to tumorigenesis. All three endometrioid ovarian tumors containing *POLE* proofreading domain mutations consisted almost entirely of the previously reported *POLE* mutation signature (TCT \> TAT, TCG \> TTG, TTT \> TGT; Signature 10) (<http://cancer.sanger.ac.uk/cosmic/signatures>)^[@CR38]^ (Fig. [2A,B](#Fig2){ref-type="fig"}). This signature was visible in the tumor-only analysis despite the lower somatic mutation specificity we have previously observed (Teer *et al*. unpublished observation). In ES samples, we observed signature 1b "Age" (likely age-related cytosine-deamination) in all samples and signature 18, which has unknown etiology, as the predominant signature in two samples of different histologies (OV10: mucinous and OV6: endometrioid) (Fig. [3A,C](#Fig3){ref-type="fig"}).Figure 3Mutational landscape across non-serous ovarian tumors. Left: (**A**) Circos plot display detected somatic alterations in Exome Sequencing (ES) tumors. Right: From outmost to inner most ring, chromosome ideogram, number of samples with mutations (light grey, increasing towards outside), number of samples with amplification (light red, increasing towards outside), numbers of samples with deletion (light blue, increasing towards inside). Dark blue slices highlight recurrent features: counterclockwise from top-left: *PIK3CA* mutations, amplification in *MYC* region, lack of mutations or deletions in *TP53* region.

Copy number alterations {#Sec8}
-----------------------

Tumor specific copy number alterations (CNA) were examined in the ES dataset. A median of 25 events was observed in each sample (range 5--192) covering a median of 76,303,334 bases (range 1,818,739--661,026,741) (Supplementary Table [7](#MOESM2){ref-type="media"}). Although many events were observed in OV7, we suspected these were unreliable due to the very low coverage in the sample from normal plasma, and did not consider this sample further. As many of the alterations were large (median = 236,356 bases, range 1,291--47,327,598 bases), genes that have been previously described as cancer drivers^[@CR39]^ were identified in the CNA regions.

Between 0 and 13 driver genes fell in copy number altered regions in each sample (Supplementary Table [8](#MOESM2){ref-type="media"}). Driver genes in amplified segments included *FGFR3*, *MYC*, *KRAS*, *EXT1*, and *PTEN*. Genes in deleted segments included *STK11*, *NF2*, *CHEK2*, *PMS2*, *CDKN2A*, and *FANCA* (Fig. [3](#Fig3){ref-type="fig"}). No sample contained a copy number alteration overlapping *TP53*, *BRCA1* or *BRCA2* (Fig. [3](#Fig3){ref-type="fig"}, Supplementary Table [8](#MOESM2){ref-type="media"}). Recent TCGA genomic classifications of high-grade serous ovarian adenocarcinoma and endometrial carcinomas revealed high levels of somatic CNAs in high grade serous ovarian and serous endometrial tumors, including recurrent amplifications in *MYC*, and *CCNE1*. We observed fewer CNAs in non-serous ovarian tumors, including only 2 samples with a *MYC* amplification and no samples with a *CCNE1* amplification.

Interestingly, sample OV3, an endometrioid tumor from the youngest individual in our cohort (diagnosed at 28 years of age) had the most CNAs. This tumor had the third lowest number of mutations with no identified common cancer mutations (Supplementary Table [4](#MOESM2){ref-type="media"}; Fig. [1](#Fig1){ref-type="fig"}). Altered driver genes in OV3 were mainly amplified, and included *NOTCH2*, *ALK*, *PIK3R1*, and *MET*. Two tumor suppressor genes were also amplified: *PTEN* and *CDKN2A*. Only one deletion was observed, which contained *PMS2*.

Discussion {#Sec9}
==========

Here, we performed exome sequencing of ten incident cases of non-serous stage 1 ovarian neoplasms to determine somatic mutations and copy number alterations. We also performed target gene sequencing for 1,321 genes in 28 non-serous tumors to explore the mutation landscape of non-serous ovarian tumors. A limitation of our ES cohort study is a relatively small sample size and reported frequencies should be taken with caution. Despite this limitation, the availability of normal matched DNA allowed an improved identification of relevant variants. We also used an additional independent cohort. The data integration and comparison with publically available data led to five main conclusions.

First, non-serous ovarian tumors seem to be distinct from serous subtypes in their prevalence of *TP53* pathogenic variants. While previous studies have reported mutations in 96% of high grade serous epithelial tumors^[@CR8]^, only one ES sample (OV8; mucinous) had a *TP53* mutation and no samples had deletions in the region. We examined the fraction of bases with depth of coverage ≥ 10 across the *TP53* gene, and found an average of 73.7% per sample, suggesting our coverage was sufficient to have observed mutations. In the TGS cohort, mutations were prevalent in mucinous (4/7, 57%), endometrioid (6/20, 30%) and clear cell (1/5, 20%) subtypes but still markedly lower than high grade serous. This is line with previous studies of clear cell carcinomas reporting 10--15% *TP53* mutation frequency^[@CR9],\ [@CR40]^. Interestingly, comparative studies of *TP53* mutations in uterine cancer also reports widely different mutation frequencies between the endometrioid (11.4--17%) and serous carcinomas (\>90%)^[@CR36],\ [@CR41]^.

Second, a small but significant fraction of endometrioid tumors display mutations in the proofreading domain of *POLE*, and mutations are not found in other non-serous subtypes. One ES sample (OV4; endometrioid) harbored a *POLE* mutation in the proofreading domain, and showed a mutational signature matching a previously reported signature of *POLE* deficiency^[@CR38]^. In the TGS set we observed recurrent *POLE* mutations in 14% (2/14) of endometrioid ovarian cancers. A screen for *POLE* mutations in a study of 251 Chinese samples of different subtypes of ovarian carcinomas, identified mutations in 3 out of 37 (8.1%) patients with ovarian endometrioid carcinoma, but not observed in the other subtypes^[@CR42]^. Interestingly, *POLE* hotspot mutations were found in 7% (17/248) of uterine carcinomas, all of endometrioid histology^[@CR36]^.

Third, we confirmed the high prevalence (5/6; 83%) of pathognomonic mutations in *FOXL2* in adult granulosa cell tumors. This is consistent with existing reports showing a prevalence ranging from 70.4% to 100%^[@CR43]--[@CR50]^.

Fourth, different non-serous subtypes have distinct mutation profiles. *KRAS* mutations are observed in significant fraction of mucinous and, to a lesser extent, in endometrioid but much less frequently (0.6%; 2/316) in high grade serous ovarian tumors^[@CR8]^. A total of 71% (5/7) of mucinous samples carried mutations in *KRAS*, confirming its high frequency in this subtype^[@CR51]--[@CR53]^. We also observed 20% (4/20) of endometrioid tumors with mutations in *KRAS*. Mutations in *PIK3CA* and *ARID1A* are the most frequent alteration in clear cell carcinomas found in combination in 2/5 (40%) of all CCC tumors in the present study. Sequencing of 97 OCCC tumors identified a high frequency of mutations in *PIK3CA* (33%) and in *TP53* (15%)^[@CR9]^.

Finally, the finding that deletion in genes implicated in the DNA damage response are relatively common suggest that therapeutic approaches targeting these pathways, such as the use of PARP inhibitors may be provide effective options in treatment. In summary, our results show that non-serous ovarian tumors are mutationally distinct from serous ovarian tumors. Interestingly, a similar but not identical mutational profile can be found in endometrioid ovarian and endometrioid uterine tumors. These similarities support the link between endometrioid ovarian cancers and endometriosis^[@CR31]^. Our findings also offer molecular evidence to support continued distinction of non-serous ovarian cancers by histology, and may offer the opportunity for future work to investigate subtype-specific interventions targeting unique molecular alterations.

Materials and Methods {#Sec10}
=====================

Participants {#Sec11}
------------

For the Exome Sequencing (ES) cohort all subjects were women between the ages of 28 and 63 (median 51) from Moffitt Cancer Center. Tumor and matched normal samples were retrieved from Moffitt's Total Cancer Care tissue bank. Tumor samples for sequencing were selected to have \>80% tumor cellularity. Six endometrioid, three mucinous, and one granulosa cell ovarian tumors were sequenced (Table [1](#Tab1){ref-type="table"}). The study was approved by the Institutional Review board of the University of South Florida and all methods were performed in accordance with the relevant guidelines and regulations.

For the Target Gene Sequencing (TGS) cohort all samples were from the Total Cancer Care tissue bank. Patients were women between the ages of 30 and 79 (median 60) diagnosed in 1993--2012. Tumors underwent macrodissection to achieve \>80% tumor cellularity in subsequent molecular studies. Samples were grouped by subtype: fourteen endometrioid, four mucinous, five clear cell, and five granulosa cell tumors were target sequenced (Table [2](#Tab2){ref-type="table"}). All patients in both cohorts have provided informed consent under the Total Cancer Care protocol.

Pathology review {#Sec12}
----------------

We conducted a pathology review of all 10 cases used in exome sequencing. Details of the findings are presented in Table [1](#Tab1){ref-type="table"}. Pathology reviews performed on hematoxylin and eosin (H&E) stained sections from a formalin-fixed paraffin-embedded (FFPE) block made during tissue acquisition at Moffitt's Tissue Bank. Samples for sequencing were derived from the same dissected tumor samples used for FFPE and pathology review. For samples OV2, OV6, OV8, and OV9, original H&E sections were not available and new cuts were made from the original corresponding FFPE blocks and stained. In these cases it is possible that the section may not represent the local tumor section used for sequencing. Representative images are shown in Supplementary Figure [3](#MOESM1){ref-type="media"}.

DNA isolation {#Sec13}
-------------

DNAs from snap frozen ovarian tumor and from normal uterus were isolated using Qiagen DNeasy Blood & Tissue Kit (Qiagen). DNA from blood was isolated using Qiagen Gentra Puregene Blood Kit or Qiagen PAXgene blood DNA kit.

Exome Sequencing {#Sec14}
----------------

Paired-end libraries were constructed and whole exome capture was performed using Roche NimbleGen SeqCap EZ v3 (Roche). Captured libraries were sequenced using 100 base-pair reads on an Illumina HiScanSQ platform (Illumina, Inc., San Diego, CA) following the manufacturer's protocols. Reads were aligned to the human genome reference hs37d5 using the Burrows-Wheeler Aligner (BWA)^[@CR54]^. The Genome Analysis ToolKit (GATK)^[@CR55]^ was used for insertion/deletion realignment, and quality score recalibration.

Somatic mutations were detected with either Strelka^[@CR56]^ or MuTect^[@CR57]^. Strelka 1.0.13 was run with default settings except the following: ssnvNoise = 0.00000005, sindelNoise = 0.0000001. MuTect 1.1.4 was run with default settings except: max_alt_alleles_in_normal_count = 3, max_alt_allele_in_normal_fraction = 0.05. ANNOVAR^[@CR58]^ was used to annotate variants. Final read depth averaged 39.2×, and a median of \~87% of bases across samples had ≥10 reads. Coverage in each sample across genes of interest can be seen in Supplementary Figure [2](#MOESM1){ref-type="media"}. Copy number alterations were detected using EXCAVATOR^[@CR59]^. Circos was used for visualization of somatic alterations^[@CR60]^. Blood was unavailable for case OV7, and although plasma was subjected to exome capture, sequencing coverage was low (0.2% target bases having ≥10 reads) and duplicate rates were high (87%) preventing sensitive tumor/normal mutation detection. Case OV7 was analyzed with GATK, and mutations were enriched by filtering out known variants.

We also examined normal DNA to identify germline mutations implicated in ovarian cancer in breast/ovarian cancer families or in Lynch syndrome^[@CR30],\ [@CR61]--[@CR63]^: *ATM, BARD1, BRCA1*, *BRCA2*, *BRIP1, CDH1, CHEK2, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1*, *PMS2, PTEN, RAD50*, *RAD51C*, *RAD51D, STK11*, and *TP53*.

Targeted Gene Sequencing {#Sec15}
------------------------

Target gene capture was performed using SureSelect custom designs (Agilent Technologies, Inc., Santa Clara, CA) targeting 1,321 genes (Supplementary Table [2](#MOESM2){ref-type="media"}). Sequencing was performed using an Illumina GAIIx sequencing platform (Illumina, Inc., San Diego, CA) at the Beijing Genomics Institute (BGI, Shenzhen, China).

Sequences were aligned to the human genome reference hs37d5 using the Burrows-Wheeler Aligner (BWA)^[@CR54]^. The Genome Analysis ToolKit (GATK)^[@CR55]^ was used for insertion/deletion realignment, quality score recalibration, and variant identification. ANNOVAR^[@CR58]^ was used to annotate mutations. Matched normal samples were not available for comparison so somatic mutations were enriched via population filtering, including 1000 Genomes and 238 unmatched normal samples. Final read depth averaged \~140x across the targeted regions and a median of \~94% of bases across samples had ≥10 reads (Supplementary Figure [2](#MOESM1){ref-type="media"}).

TCGA mutation frequencies {#Sec16}
-------------------------

Mutation frequencies were downloaded from cBioportal^[@CR64],\ [@CR65]^ using the "Ovarian Serous Cystadenocarcinoma^[@CR8]^ and "Uterine Corpus Endometrial Carcinoma^[@CR36]^.

Mutation signatures {#Sec17}
-------------------

Mutational signatures were derived from the ES samples using previously described methods^[@CR38]^. Curated and updated ICGC (International Cancer Genomics Consortium) signatures can be found at <http://cancer.sanger.ac.uk/cosmic/signatures>.

Electronic supplementary material
=================================

 {#Sec18}

Supplementary Data Supplementary Tables 2--11

**Electronic supplementary material**

**Supplementary information** accompanies this paper at doi:10.1038/s41598-017-10432-9

**Publisher\'s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work was supported by grants from the Phi Beta Psi Foundation, Ovarian Cancer Research Foundation (258807), and in part by the Cancer Informatics and the Molecular Genomics Core Facilities at the Moffitt Cancer Center through its NCI CCSG grant (P30-CA76292). We thank Ross Myers, Lori Kirchoff, Michelle Fournier, Vonetta Williams, and Marek Wloch for technical assistance.

S.Y. and C.Z. generated data; J.K.T. and A.N.M. designed the study; J.K.T., A.G., S.V.N., and A.N.A.M. analyzed data and prepared the manuscript. All authors approved the manuscript.

Competing Interests {#FPar1}
===================

The authors declare that they have no competing interests.
